Click on image to view larger version.

Figure 7 In vivo effects of SU11218. (A) The SU11218 significantly inhibited the Ad-MV response after stenting at 1 week and 4 weeks. (B) The SU11218 resulted in approximately 80% reduction in the amount of IH at 4 weeks. Abbreviations as in Figures 2 and 3.